Lanthanide ions, Ln(III), are of interest in the treatment of bone density disorders because they are found to accumulate preferentially in bone (in vivo), have a stimulatory effect on bone formation, and exhibit an inhibitory effect on bone degradation (in vitro), altering the homeostasis of the bone cycle. In an effort to develop an orally active lanthanide drug, a series of 3-hydroxy-4-pyrid...

In this study, we investigate the impact of N-methylation on electronic and photophysical properties both homoleptic heteroleptic Ru(II) bis-terpyridine complexes based recently reported ligand 4’-(4-bromophenyl)-4,4’’’: 4’’,4’’’’-dipyr-idinyl-2,2’ : 6’,2’’-terpyridine (Bipytpy), with pyridine substituents in 4- 4’’-position. The first reduction methylated takes place at pyridinium site is obse...

4-[5-(Pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile (FYX-051) is a potent inhibitor of bovine milk xanthine oxidoreductase (XOR). Steady-state kinetics study showed that it initially behaved as a competitive-type inhibitor with a K(i) value of 5.7 × 10(-9) M, then after a few minutes it formed a tight complex with XOR via a Mo-oxygen-carbon atom covalent linkage, as reported previ...

The synthesis, characterization and biological activity of Cu(II) and Ni(II) complexes derived from tridentate Schiff base ligand 3-hydroxy-4-(pyridine-2-yl methylene amino) benzoic acid (HL) was obtained by the condensation of 2-Pyridine carboxaldehyde with 4-amino 3-hydroxy benzoic acid has been described. The complexes were characterized based on elemental analyses, molar conductivity measur...